Silence Therapeutics plc — Director's Dealing 2019

Sep 30, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2226O

Silence Therapeutics PLC

30 September 2019

Director/PDMR Shareholding

September 30th, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on September 30th 25,000 Shares were purchased by Iain Ross, Non-Executive Chairman of the Company, at £1.88 per share.

Following this purchase, Iain Ross is interested in 25,000 ordinary shares (0.03%) of the issued shared capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Iain Ross

2.

Reason for the notification

a)

Position / status

Non-Executive Chair

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

b)

LEI

213800SSURRJBX85SQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each in Silence Therapeutics plc

ISIN for Silence Therapeutics plc Ordinary Shares:

GB00B9GTXM62

b)

Nature of the transaction

Purchase of Ordinary Shares in Silence Therapeutics plc

c)

Prices(a) and volume(s)

Price	Volume
£1.88	25,000

d)

Aggregated information

- Aggregated volume

- Price

25,000 Ordinary Shares

£47,000.00

e)

Date of the transaction

30 September 2019

f)

Place of the transaction

London Stock Exchange, AIM

Enquiries:

Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray [email protected]	Tel: +44 (0) 20 3709 5700
US IR Westwicke Partners Peter Vozzo [email protected]	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBUGDCRUXBGCG